Herpes Vaccine Candidate Advances in 2023 - Precision …
WEBJan 8, 2023 · When BioNTech SE announced that the first person was dosed in a first-in-human Phase 1 clinical trial with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, there was much enthusiasm generated by millions of people. BioNTech's placebo-controlled, observer-blinded, two-dose-escalation study was launched on ...
U.S. Government Takes Herpes Vaccine Development Lead
WEBApr 4, 2024 · To address this shortcoming, the U.S. government issued a Notice of Special Interest (NOSI) NOT-AI-24-028 on March 27, 2024, intending to stimulate additional focus on developing diagnostics, therapeutics, and vaccines targeting HSV. This NOSI, issued by the U.S. National Institute of Allergy and Infectious Diseases, focuses on furthering the ...
Multi-Country Herpes Immunotherapy Clinical Study Continues
WEBMar 5, 2024 · This multi-country research study is recruiting 332 healthy participants aged 18-40 years or those aged 18-60 years with recurrent genital herpes. Known as GSK3943104A, GSK Study #215336 is forecasted to conclude in May 2026. This HSVTI study will explore different formulations and be conducted in two parts:
HSV Treatment Readies for Approval — Precision Vaccinations News
WEBMar 29, 2023 · A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV). As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of …
Three Novel Immune-based Therapies for HIV Cure Launch Clinical …
WEBApr 22, 2024 · To address this clinical need, ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of A5374, a phase 1/2a study evaluating the safety, tolerability, and antiviral effect of a novel combination regimen that includes therapeutic T-cell vaccines, two broadly neutralizing antibodies ...
What’s the Difference Between Shingles and Chickenpox Vaccines?
WEBNov 2, 2017 · Conversely, the Zostavax, the traditional chickenpox vaccine, offers protection against shingles by only 51 percent, and the risk of PHN by 67 percent, according to the CDC. In addition, Zostavax’s effectiveness appears to last just five years, according to the CDC. Like every vaccine, Shingrix has the potential for side effects.
Tracking Polio Eradication Progress in 2024 - Precision …
WEBGPEI polio case map April 2, 2024. (Precision Vaccinations News) The reliable and timely detection of poliovirus cases is a critical component of polio eradication programs wrote the U.S. CDC. Since 1988, the number of polio cases caused by wild poliovirus (WPV) has declined by 99.9%, and eradication of WPV serotypes 2 and 3 has been certified.
Welcome to Precision Vaccinations News
WEB2 days ago · Dengue. Dengue Could Soon Infect 4 Billion PeopleMosquito-transmitted viruses such as Chikungunya and Zika are impacting human health in 2024. Canada Contributes $111 Million to Defeat PolioPolio vaccines available in September 2024. Brazil Leads The Americas in Dengue CasesDengue vaccination offered in Brazil in 2024.
Ruvidar™ Found Effective in Destroying Herpes Simplex Virus
WEBSep 4, 2024 · However, Acyclovir will not cure herpes. To address this need, Theralase® Technologies Inc. today announced that its lead drug formulation, Ruvidar™, could be more effective in destroying HSV-1 than Acyclovir. Another important pre-clinical observation is that Acyclovir could not prevent HSV-1 replication if added one day after infection.
Chronic Hepatitis B Treatment Receives U.S. FDA Fast Track …
WEBFeb 13, 2024 · GSK plc announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). GSK said on February 12, 2024, Bepirovirsen is the only single agent in phase III development that has shown the potential to achieve clinically meaningful functional cure ...
- Some results have been removed